Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00466687 · ClinicalTrials.gov registry record · Phase 2
Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma
A Phase 2 study of Melanoma, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 4
- Study locations
NCT00466687: Completed Phase 2 study of Melanoma, sponsored by Vanderbilt-Ingram Cancer Center.
NCT00466687 is a Phase 2 study of Melanoma that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 34 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00466687, a Phase 2 study of Melanoma, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 4
- Study locations
Study Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving erlotinib together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving erlotinib together with bevacizumab works in treating patients with stage IV melanoma.
Primary Outcome
Per Response Evaluation Criteria in Solid Tumor (RECIST): Progressive disease (PD): \>=20% increase in sum of longest diameter (LD) of target lesion(s), taking as reference smallest sum LD recorded since treatment started. Complete response (CR): disappearance of all target lesions. Partial response (PR): \>=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as P
Conditions Studied
Interventions
- GENETIC gene expression analysis
- BIOLOGICAL bevacizumab
- DRUG erlotinib hydrochloride
- GENETIC fluorescence in situ hybridization
- OTHER immunologic technique
Study Locations (4)
Tennessee
- Vanderbilt-Ingram Cancer Center - Cool Springs - Nashville
- Vanderbilt-Ingram Cancer Center at Franklin - Nashville
- Sarah Cannon Research Institute - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2004-09 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
What the finished NCT00466687 record still lists
NCT00466687 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00466687 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00466687 about?
NCT00466687 is a clinical study titled "Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma". RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them o...
What is the current status of trial NCT00466687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2004-09. Estimated completion is 2008-09.
What conditions does trial NCT00466687 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00466687?
The interventions under investigation include: gene expression analysis (GENETIC), bevacizumab (BIOLOGICAL), erlotinib hydrochloride (DRUG), fluorescence in situ hybridization (GENETIC), immunologic technique (OTHER).
Who is sponsoring clinical trial NCT00466687?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00466687 being conducted?
This trial has 4 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00466687's enrollment target sits among peer trials
34 190th of 266 higher than 76 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia